News

Three children in US Customs and Border Protection custody have died since December 2018, partially due to influenza. Now, the infectious disease community is rallying for vaccination for migrants in detention facilities.

DNA barcoding, an emerging technique for identifying fungal pathogens, from 2 regions could help speed up diagnosis and treatment, a new study found.

William Schaffner, MD, breaks down the new ACIP guideline recommendation, the pediatric benefit of PCV13 which drove the decision, and means by which it can improve clinical decisions surrounding vaccination.

The study has achieved its primary objective, demonstrating that administration every 8 weeks is as effective in maintaining viral suppression compared with monthly administration.

According to the CDC, serologic assays that use a second enzyme immunoassay are acceptable alternatives to western immunoblot assays.

Enterovirus-specific antibodies were detected in the cerebrospinal fluid of 79% (11 of 14) of the AFM cases included in a new study.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

Although antibodies normally shield us from infection, a new study suggests that certain maternal antibodies may actually make it easier for Zika virus to gain a foothold and cause birth defects.

The first Contagion® Connect podcast features a conversation with Dr. Alexandra Phelan about the impact of pandemic bonds in the ongoing Ebola outbreak in the DRC.

Lactic acid produced by bacteria in the vagina may help protect women from Chlamydia trachomatis infection, a new study suggests.

Parents seeking medical exclusions for their children must now have their physician fill out a state form explaining specifically why the exemption is warranted.

A recent study provides what may be the first in-depth examination of the molecular mechanism of biotransformation of a large number of orally administered agents by the human gut microbiota.

Variances in collection and siloed efforts are hurting this outbreak response.

A research team’s latest study offers new insights into a weak point on the Lassa virus surface and the neutralizing antibodies capable of targeting it.

Both the oral and intravenous formulations of the novel pleuromutilin antibiotic were shown to be efficacious in 2 phase 3 studies.

The HITS consortium provided a wealth of knowledge on infection prevention topics, but also served as an environment for frank and honest discussions regarding Legionella management.

Daptomycin plus β-lactam therapy was associated with reduced composite definition for clinical failure but, worryingly, was also linked to increased risk of acute kidney injury.

The vaccine was based on a recombinant protein subunit (CTH522) and evaluated in a prime-boost immunization schedule.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of August 11, 2019.

We’ve rounded up a list of important US Food and Drug Administration and US Department of Agriculture recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Evidence demonstrates that antimicrobial therapy with an anti-staphylococcal β-lactam antibiotic is the gold standard for treatment of SAB caused by MSSA, but confusion about which agent—particularly cefazolin versus an anti-staphylococcal penicillin—is preferred remains an unanswered question

The CDC hopes the case of a patient who was hospitalized in Maryland following a hospitalization in Kenya will help raise awareness of the importance of C auris screening.

Transitioning from a child born with HIV into an adult living with HIV often means less adherence to antiretroviral medication therapies and a lower level of viral suppression. A new study delves into some possible reasons why.

As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.

Patients and health care professionals alike cite significant issues with education and emotion surrounding MDROs.

The research team deciphered that the nitazoxanide boosts the ability of specific viral sensors to detect Ebola when infected, which then sparks an antiviral immune response.

The approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.